Last reviewed · How we verify
HY-0102
At a glance
| Generic name | HY-0102 |
|---|---|
| Also known as | HY-0102 injection |
| Sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- A Study of HY-0102 in Patients With Advanced Solid Tumors (PHASE1)
- HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HY-0102 CI brief — competitive landscape report
- HY-0102 updates RSS · CI watch RSS
- Shanghai YingLi Pharmaceutical Co. Ltd. portfolio CI